172 related articles for article (PubMed ID: 23653049)
1. Differences in metabolic and mitogenic signallingof insulin glargine and AspB10 human insulin in rats [corrected].
Tennagels N; Welte S; Hofmann M; Brenk P; Schmidt R; Werner U
Diabetologia; 2013 Aug; 56(8):1826-34. PubMed ID: 23653049
[TBL] [Abstract][Full Text] [Related]
2. Metabolic effect and receptor signalling profile of a non-metabolisable insulin glargine analogue.
Werner U; Korn M; Schmidt R; Wendrich TM; Tennagels N
Arch Physiol Biochem; 2014 Oct; 120(4):158-65. PubMed ID: 25144413
[TBL] [Abstract][Full Text] [Related]
3. Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor.
Yehezkel E; Weinstein D; Simon M; Sarfstein R; Laron Z; Werner H
Diabetologia; 2010 Dec; 53(12):2667-75. PubMed ID: 20835859
[TBL] [Abstract][Full Text] [Related]
4. Insulin analogues differently activate insulin receptor isoforms and post-receptor signalling.
Sciacca L; Cassarino MF; Genua M; Pandini G; Le Moli R; Squatrito S; Vigneri R
Diabetologia; 2010 Aug; 53(8):1743-53. PubMed ID: 20424816
[TBL] [Abstract][Full Text] [Related]
5. Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel.
ter Braak B; Siezen CL; Kannegieter N; Koedoot E; van de Water B; van der Laan JW
Arch Toxicol; 2014 Apr; 88(4):953-66. PubMed ID: 24464500
[TBL] [Abstract][Full Text] [Related]
6. In vitro metabolic and mitogenic signaling of insulin glargine and its metabolites.
Sommerfeld MR; Müller G; Tschank G; Seipke G; Habermann P; Kurrle R; Tennagels N
PLoS One; 2010 Mar; 5(3):e9540. PubMed ID: 20209060
[TBL] [Abstract][Full Text] [Related]
7. IGF-1 receptor signalling determines the mitogenic potency of insulin analogues in human smooth muscle cells and fibroblasts.
Eckardt K; May C; Koenen M; Eckel J
Diabetologia; 2007 Dec; 50(12):2534-43. PubMed ID: 17898992
[TBL] [Abstract][Full Text] [Related]
8. Effect of insulin analogues on insulin/IGF1 hybrid receptors: increased activation by glargine but not by its metabolites M1 and M2.
Pierre-Eugene C; Pagesy P; Nguyen TT; Neuillé M; Tschank G; Tennagels N; Hampe C; Issad T
PLoS One; 2012; 7(7):e41992. PubMed ID: 22848683
[TBL] [Abstract][Full Text] [Related]
9. Effect of the long-acting insulin analogues glargine and degludec on cardiomyocyte cell signalling and function.
Hartmann T; Overhagen S; Ouwens DM; Raschke S; Wohlfart P; Tennagels N; Wronkowitz N; Eckel J
Cardiovasc Diabetol; 2016 Jul; 15():96. PubMed ID: 27422524
[TBL] [Abstract][Full Text] [Related]
10. ASPB10 insulin induction of increased mitogenic responses and phenotypic changes in human breast epithelial cells: evidence for enhanced interactions with the insulin-like growth factor-I receptor.
Milazzo G; Sciacca L; Papa V; Goldfine ID; Vigneri R
Mol Carcinog; 1997 Jan; 18(1):19-25. PubMed ID: 9022809
[TBL] [Abstract][Full Text] [Related]
11. Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10.
Hansen BF; Glendorf T; Hegelund AC; Lundby A; Lützen A; Slaaby R; Stidsen CE
PLoS One; 2012; 7(5):e34274. PubMed ID: 22590494
[TBL] [Abstract][Full Text] [Related]
12. Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells.
Bähr M; Kolter T; Seipke G; Eckel J
Eur J Pharmacol; 1997 Feb; 320(2-3):259-65. PubMed ID: 9059862
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of signalling properties mediated by long-acting insulin analogue glargine and detemir in target cells of insulin.
Wada T; Azegami M; Sugiyama M; Tsuneki H; Sasaoka T
Diabetes Res Clin Pract; 2008 Sep; 81(3):269-77. PubMed ID: 18585815
[TBL] [Abstract][Full Text] [Related]
14. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells.
Weinstein D; Simon M; Yehezkel E; Laron Z; Werner H
Diabetes Metab Res Rev; 2009 Jan; 25(1):41-9. PubMed ID: 19145584
[TBL] [Abstract][Full Text] [Related]
15. Effects of the long-acting insulin analog insulin glargine on cultured human skeletal muscle cells: comparisons to insulin and IGF-I.
Ciaraldi TP; Carter L; Seipke G; Mudaliar S; Henry RR
J Clin Endocrinol Metab; 2001 Dec; 86(12):5838-47. PubMed ID: 11739448
[TBL] [Abstract][Full Text] [Related]
16. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.
Kurtzhals P; Schäffer L; Sørensen A; Kristensen C; Jonassen I; Schmid C; Trüb T
Diabetes; 2000 Jun; 49(6):999-1005. PubMed ID: 10866053
[TBL] [Abstract][Full Text] [Related]
17. Concentrations of insulin glargine and its metabolites during long-term insulin therapy in type 2 diabetic patients and comparison of effects of insulin glargine, its metabolites, IGF-I, and human insulin on insulin and igf-I receptor signaling.
Varewijck AJ; Yki-Järvinen H; Schmidt R; Tennagels N; Janssen JA
Diabetes; 2013 Jul; 62(7):2539-44. PubMed ID: 23569175
[TBL] [Abstract][Full Text] [Related]
18. Insulin receptor phosphorylation by endogenous insulin or the insulin analog AspB10 promotes mammary tumor growth independent of the IGF-I receptor.
Gallagher EJ; Alikhani N; Tobin-Hess A; Blank J; Buffin NJ; Zelenko Z; Tennagels N; Werner U; LeRoith D
Diabetes; 2013 Oct; 62(10):3553-60. PubMed ID: 23835331
[TBL] [Abstract][Full Text] [Related]
19. Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53R270H/⁺WAPCre mouse model.
ter Braak B; Siezen C; Speksnijder EN; Koedoot E; van Steeg H; Salvatori DC; van de Water B; van der Laan JW
Breast Cancer Res; 2015 Feb; 17(1):14. PubMed ID: 25848982
[TBL] [Abstract][Full Text] [Related]
20.
Wronkowitz N; Hartmann T; Görgens SW; Dietze-Schroeder D; Indrakusuma I; Choi IY; Park SH; Lee YM; Kwon SC; Kang Y; Hompesch M; Eckel J
Diabetes Obes Metab; 2017 Dec; 19(12):1722-1731. PubMed ID: 28497570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
